Ruiwen Zhang sareng Robert L. Boblitt ti Universitas Houston parantos ngembangkeun ubar kanker pankréas énggal. The research was published in the Journal of Cancer Research. The drug targets two genes at the same time, and this breakthrough achievement is of great significance for the treatment of aggressive and deadly kanker pancreatic.
Ubar ieu ogé diarepkeun janten kerangka ngembangkeun obat pikeun ngubaran bentuk kanker atanapi panyakit sanés. Kanker pankreas lumangsung nalika sél pankreas mimiti ngalobaan kaluar tina kadali sareng janten lumps, sareng sél kanker anu hasilna tiasa nyerang bagian awak anu sanés. Kaseueuran kangker dimimitian di daérah pankréas anu ngahasilkeun énzim pencernaan. Gejala kaasup nyeri beuteung atanapi burih, leungitna beurat anu teu disangka-sangka, sareng jaundice (kulit konéng). In addition, a person’s urine may appear dark yellow and itchy skin. There are two oncogenes associated with pancreatic cancer. There are two main ways for the drug to inhibit pancreatic cancer. They activate the nuclear factor of T cell 1 (NFAT1) and murine double microparticle 2 (MDM2), respectively. The latter gene regulates a tumor suppressor gene called p53. When there is no tumor suppressor p53, MDM2 can cause cancer. NFAT1 is used to up-regulate the expression of MDM2, thereby promoting tumor growth. Factors related to diet, nutrition and the environment can lead to increased levels of these factors in the cell.
Nalika nyarioskeun pamanggihan ieu, Dr. Zhang nyarios yén kabutuhan klinis ubar anyar, épéktip sareng aman pikeun panyakit kanker pankreas teu acan kacumponan. Timuan kami ngagambarkeun kamajuan utama dina panilitian kanker. Anjeunna nambahan: "Kaseueuran ubar ngan ukur sasaran hiji faktor. Kami ngaidentifikasi sanyawa anu nargétkeun dua gén anu aya hubunganana sareng kanker. "Obat énggal mangrupikeun sanyawa sintétik MA242. Ubar ieu tiasa nyéépkeun dua protéin dina waktos anu sami, sahingga ningkatkeun efisiensi maéhan tumor.
